166 related articles for article (PubMed ID: 38720335)
1. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study.
Qarni TN; Jones FJS; Drachman B; Khella S; Pieretti J; Bustamante NS; Karam C
Orphanet J Rare Dis; 2024 May; 19(1):191. PubMed ID: 38720335
[TBL] [Abstract][Full Text] [Related]
2. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
[TBL] [Abstract][Full Text] [Related]
3. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
Luigetti M; Antonini G; Di Paolantonio A; Gentile L; Grandis M; Leonardi L; Lozza A; Manganelli F; Mazzeo A; Mussinelli R; My F; Obici L; Maria Pennisi E; Romozzi M; Russo M; Sabatelli M; Salvalaggio A; Tagliapietra M; Tozza S
Eur J Neurol; 2022 Jul; 29(7):2148-2155. PubMed ID: 35289020
[TBL] [Abstract][Full Text] [Related]
4. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
[TBL] [Abstract][Full Text] [Related]
5. Deterioration after Liver Transplantation and Transthyretin Stabilizer Administration in a Patient with ATTRv Amyloidosis with a Leu58Arg (p.Leu78Arg) TTR Variant.
Hikishima S; Sakai K; Akagi A; Yamaguchi H; Shibata S; Hayashi K; Nakano H; Kanemoto M; Usui Y; Taniguchi Y; Komatsu J; Nakamura-Shindo K; Nozaki I; Hamaguchi T; Ono K; Iwasa K; Yamada M
Intern Med; 2022 Aug; 61(15):2347-2351. PubMed ID: 35283385
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study.
Albenque G; Bézard M; Kharoubi M; Odouard S; Lunati A; Poullot E; Zaroui A; Teiger E; Hittinger L; Audard V; El Karoui K; Funalot B; Fanen P; Damy T; Oghina S
Amyloid; 2023 Dec; 30(4):407-415. PubMed ID: 37377439
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D; Tournev IL; Taylor MS; Coelho T; Planté-Bordeneuve V; Berk JL; González-Duarte A; Gillmore JD; Low SC; Sekijima Y; Obici L; Chen C; Badri P; Arum SM; Vest J; Polydefkis M;
Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
[TBL] [Abstract][Full Text] [Related]
8. [Gene therapy options for hereditary transthyretin-related amyloidosis].
Schilling M
Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
[TBL] [Abstract][Full Text] [Related]
9. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
[No Abstract] [Full Text] [Related]
10. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
[TBL] [Abstract][Full Text] [Related]
12. [Neurological manifestations of ATTR amyloidosis].
Pernice HF; Hahn K
Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
[TBL] [Abstract][Full Text] [Related]
13. Disease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy.
Ueda M; Misumi Y; Nomura T; Tasaki M; Yamakawa S; Obayashi K; Yamashita T; Ando Y
Ann Neurol; 2024 Feb; 95(2):230-236. PubMed ID: 38053464
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
15. Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis.
Socie P; Benmalek A; Cauquil C; Piekarski E; Kounis I; Eliahou L; Rousseau A; Rouzet F; Echaniz-Laguna A; Samuel D; Adams D; Slama MS; Algalarrondo V
Amyloid; 2023 Sep; 30(3):303-312. PubMed ID: 36795029
[TBL] [Abstract][Full Text] [Related]
16. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
Meléndrez-Balcázar E; Aranda-Vela K; Cervantes-Hernández A; López-Cureño S
Am J Kidney Dis; 2024 Mar; ():. PubMed ID: 38484868
[TBL] [Abstract][Full Text] [Related]
17. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.
Caponetti AG; Sguazzotti M; Accietto A; Saturi G; Ponziani A; Giovannetti A; Massa P; Ruotolo I; Sena G; Zaccaro A; Parisi V; Bonfiglioli R; Guaraldi P; Gagliardi C; Cortelli P; Galie N; Biagini E; Longhi S
Eur J Prev Cardiol; 2024 May; 31(7):866-876. PubMed ID: 38204330
[TBL] [Abstract][Full Text] [Related]
18. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
Coelho T; Marques W; Dasgupta NR; Chao CC; Parman Y; França MC; Guo YC; Wixner J; Ro LS; Calandra CR; Kowacs PA; Berk JL; Obici L; Barroso FA; Weiler M; Conceição I; Jung SW; Buchele G; Brambatti M; Chen J; Hughes SG; Schneider E; Viney NJ; Masri A; Gertz MR; Ando Y; Gillmore JD; Khella S; Dyck PJB; Waddington Cruz M;
JAMA; 2023 Oct; 330(15):1448-1458. PubMed ID: 37768671
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
[TBL] [Abstract][Full Text] [Related]
20. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]